Add-On Therapy to Risperidonein Schizophrenia

• Status: Completed
• Trial end date: 2008-12-01

Summary

These results suggest that the DA neuroprotection provided by DM in the inflammation-related neurodegenerative models is not mediated through the NMDA receptor.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: National Cheng-Kung University Hospital
• Treatments: Dextromethorphan; Risperidone